HGH Fragment 176-191 Research Overview (also known as AOD-9604, HGH Frag, Fragment 176-191, Growth Hormone Fragment)
HGH Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone. It was developed to investigate growth-hormone-associated effects on lipid metabolism while minimizing the receptor-mediated growth, insulin-like growth factor 1 (IGF-1), and glucose effects associated with intact human growth hormone. Laboratory and animal studies have reported lipolytic and anti-adipogenic activity, but evidence in humans remains limited and inconsistent. Fragment 176-191 is not an approved medication, and claims that it produces a predictable fat-loss effect, is twelve times more potent than growth hormone, or is entirely free of metabolic risks are not established by high-quality clinical evidence.
What Is HGH Fragment 176-191?
HGH Fragment 176-191 is a laboratory-produced peptide that corresponds to residues 176 through 191 of the 191-amino-acid human growth hormone molecule. The sequence is commonly represented as Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. It was identified during research into the possibility that some of growth hormone's effects on fat metabolism reside in a region of the hormone that is separable from the structural regions responsible for growth-promoting activity. Researchers therefore investigated short growth-hormone-derived peptides as experimental tools for studying lipolysis, adipocyte biology, and energy metabolism without administering full-length growth hormone.
The principal distinction from intact human growth hormone is conceptual rather than clinically guaranteed. Full-length growth hormone binds the growth hormone receptor and can increase hepatic IGF-1 production, alter glucose tolerance, reduce insulin sensitivity, and promote sodium and water retention. Fragment 176-191 lacks the complete three-dimensional structure required for the normal endocrine actions of the intact hormone and has not been shown to reproduce the full growth-hormone/IGF-1 axis. Some preclinical studies report little or no increase in circulating IGF-1 or blood glucose after administration of related fragments; however, this should not be interpreted as proof that every preparation is metabolically neutral in humans. The often-repeated statement that Fragment 176-191 has twelve times the fat-burning potency of growth hormone comes from limited experimental comparisons and is not a validated clinical estimate.
AOD-9604 is a related, modified growth-hormone-derived peptide developed from the 176-191 region. It is frequently described in commercial material as an acetylated or otherwise chemically modified analogue, but the exact composition and manufacturing specification should be confirmed from a primary source or certificate of analysis. AOD-9604 and unmodified Fragment 176-191 are not automatically interchangeable: changes in sequence, terminal chemistry, formulation, purity, and pharmacokinetics can materially affect biological activity. Neither product is approved by major medicines regulators as a general-purpose treatment for obesity or body-composition improvement.
Research Indications
Adipose Tissue Metabolism
Lipolytic signaling
The C-terminal growth-hormone fragment has shown lipolytic activity in experimental adipose models, with effects proposed to be distinct from the full growth-hormone receptor pathway.
Reduced lipogenesis in preclinical work
Animal and laboratory studies of related 176–191 preparations have reported reduced fat accumulation and altered lipid handling; translation to meaningful human fat loss remains uncertain.
Body-Composition Research
AOD9604-related human studies
Clinical development of the related modified fragment AOD9604 explored obesity treatment, but published evidence has not established a reliable clinically important weight-loss effect.
No established therapeutic indication
HGH Fragment 176-191 is not an approved treatment for obesity, metabolic disease, or athletic body-composition modification.
Mechanistic and Safety Uncertainty
Fragment-specific pharmacology
Findings for endogenous growth hormone or recombinant HGH cannot be assumed to apply to this short peptide fragment, which may have different receptor interactions and pharmacokinetics.
Long-term outcomes are not characterized
Controlled long-duration data on cardiovascular, endocrine, reproductive, and metabolic outcomes are limited or unavailable for research-grade HGH Fragment 176-191 products.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Exploratory tolerance assessment | 100–250 mcg | Once daily | Subcutaneous |
| Community fat-loss protocol | 250–500 mcg | Once daily | Subcutaneous |
| Split-dose community protocol | 250 mcg per dose | Twice daily | Subcutaneous |
| Higher-end anecdotal use | 500–1000 mcg | Once daily | Subcutaneous |
Timing
Research-community protocols commonly place subcutaneous administration in a fasted period or between meals. This timing practice is anecdotal rather than clinically validated; avoid assuming that fasting improves efficacy, and monitor for individual tolerability concerns.
Peptide Interactions
No established direct interaction, but combined appetite reduction and caloric restriction can complicate nutritional adequacy, hydration, and interpretation of weight-change effects.
Concurrent use has not been adequately studied. Medical supervision is important where a prescribed incretin therapy is used for diabetes or obesity.
The fragment is not interchangeable with full-length HGH. Combined use lacks controlled safety data and may obscure adverse-effect attribution.
Metabolic effects are incompletely characterized. People using insulin, sulfonylureas, or other glucose-lowering medicines should not add investigational peptides without clinician oversight.
No specific pharmacologic interaction is established, though stimulant-related palpitations, anxiety, and sleep disruption can confound tolerability monitoring.
Using diuretics to accelerate scale-weight changes increases dehydration and electrolyte-risk concerns and makes body-composition outcomes difficult to interpret.
Reported Research Timeline
01Days 1–7 (reported in cited studies): no reliable visible fat-loss effect should be expected. If used, the earliest observations are generally limited to injection-site tolerability and nonspecific changes in appetite, energy, or sleep.
02Weeks 2–3 (reported in cited studies): any scale-weight movement is more likely to reflect food intake, glycogen, fluid balance, and activity than a confirmed fragment-specific effect.
03Weeks 4–6 (reported in cited studies): if tracking an outcome, use consistent waist measurements, body weight, training performance, dietary intake, and adverse-effect notes rather than relying on subjective impressions.
04Weeks 6–8 (reported in cited studies): evidence does not support a predictable response window. Lack of measurable change should not be addressed by escalating dose without medical review.
05Beyond 8 weeks: Long-term safety and sustained body-composition effects are not established. Reassess risks, product quality, and the need for clinician-guided alternatives.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
HGH Fragment 176-191 is an investigational peptide and is not an approved treatment for obesity, diabetes, or body-composition enhancement.
Avoid use during pregnancy or breastfeeding because reproductive and developmental safety data are insufficient.
People with diabetes, impaired glucose tolerance, endocrine disorders, active cancer, or a history of cancer should seek specialist medical advice before considering use.
Injection-related risks include pain, bruising, local inflammation, contamination, and infection; sterile technique and single-use supplies are essential.
Do not interpret product labeling or a stated peptide amount as proof of identity, sterility, potency, or absence of contaminants.
Seek Medical Attention If:
You develop trouble breathing, facial or throat swelling, widespread hives, fainting, or other signs of a severe allergic reaction.
An injection site becomes increasingly red, hot, swollen, severely painful, drains pus, or is accompanied by fever.
You experience chest pain, severe shortness of breath, persistent rapid heartbeat, confusion, or loss of consciousness.
You have symptoms of significant glucose disturbance, including severe shakiness, sweating, confusion, marked thirst, vomiting, or unusual weakness.
Quality Indicators
Verified Marker
Batch-specific identity and purity report
Seek an independently issued, lot-matched certificate showing peptide identity and quantitative purity, ideally supported by LC-MS and HPLC methods.
Verified Marker
Clear, traceable vial labeling
Vial and outer packaging should identify the peptide, stated content, lot number, manufacture date, storage conditions, and a traceable testing record.
Verified Marker
Appropriate lyophilized appearance
A lyophilized peptide should generally appear as a dry cake or powder without visible discoloration, moisture damage, foreign particles, or a compromised stopper.
Acceptable Range
Clear reconstitution solution
After reconstitution according to validated handling instructions, the solution should be clear and free of visible particles. Cloudiness or unexpected color warrants disposal rather than use.
Quality Concern
Missing sterility or endotoxin documentation
Purity testing alone does not establish injectable safety. Unverifiable sterility, endotoxin, fill-volume, or chain-of-custody information is a significant quality concern.
Research Citations
- Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.
Møller, N., Jørgensen, J. O. L., et al., 2009, Endocrine Reviews - Effects of growth hormone on lipolysis, lipid oxidation, and VLDL-triglyceride production in humans.
Djurhuus, C. B., Gravholt, C. H., et al., 2004, American Journal of Physiology-Endocrinology and Metabolism - Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone.
Hansen, T. K., Gravholt, C. H., et al., 2002, Journal of Clinical Endocrinology & Metabolism - Growth hormone increases regional lipolysis in the fasting state.
Gravholt, C. H., Schmitz, O., et al., 2000, Journal of Clinical Endocrinology & Metabolism
Research Focus
fat loss, lipolysis, adipose tissue, growth hormone fragment, IGF-1 neutral, obesity research, metabolic health
Frequently Asked Questions
What should researchers watch for with HGH Fragment 176-191?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with HGH Fragment 176-191?
Days 1–7 (reported in cited studies): no reliable visible fat-loss effect should be expected. If used, the earliest observations are generally limited to injection-site tolerability and nonspecific changes in appetite, energy, or sleep.
How is HGH Fragment 176-191 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →